Lifesavers · No. 26
Uterotonics for postpartum hemorrhage
When health workers measure bleeding after childbirth with a simple collection drape and respond with a bundle of treatments built around a uterotonic drug, severe bleeding falls by 60% compared with the usual, slower response.
From the E-MOTIVE trial (New England Journal of Medicine, 2023): the composite outcome occurred in 1.6% of patients in the intervention group versus 4.3% under usual care (risk ratio 0.40, 95% CI 0.32 to 0.50). The bundle pairs a uterotonic with uterine massage, tranexamic acid, IV fluids and prompt escalation to advanced care; this is not a measure of a uterotonic given alone. The World Health Organization separately recommends that every woman receive a uterotonic, typically 10 IU of oxytocin, immediately after birth to help prevent postpartum hemorrhage before it starts.
How it saves lives
After a baby is born, the uterus needs to contract firmly to close off the blood vessels that fed the placenta; when it does not, a woman can lose dangerous amounts of blood within minutes. A uterotonic drug such as oxytocin makes the uterus contract, and giving one to every woman right after birth is the World Health Organization's standard recommendation to prevent that bleeding before it starts. Detecting bleeding early and reaching for a uterotonic without delay, rather than waiting to see how bad it gets, is what actually saves lives.
The story
Postpartum hemorrhage is the leading cause of maternal death worldwide, affecting an estimated 14 million women a year and killing around 70,000 of them, mostly in poorer countries. For decades the standard response was sequential: try one treatment, wait, then try the next. The E-MOTIVE trial, run across 80 hospitals in Kenya, Nigeria, South Africa and Tanzania and published in 2023, tested a different approach: a low-cost drape that measures blood loss accurately the moment it happens, paired with a bundle of treatments, a uterotonic among them, given all at once instead of one at a time. Severe bleeding, laparotomy for bleeding, or death from bleeding occurred in just 1.6% of patients who got the bundle, against 4.3% under usual care, a 60% cut in the risk.
From the record
A trial of a set of interventions to manage postpartum haemorrhage, published in the New England Journal of Medicine, found a 60% reduction in heavy bleeding.
From the record
a primary-outcome event occurred in 1.6% of the patients in the intervention group, as compared with 4.3% of those in the usual-care group (risk ratio, 0.40; 95% confidence interval [CI], 0.32 to 0.50; P<0.001).
Asked often
How much does a uterotonic-based response reduce deaths from postpartum bleeding?
In the E-MOTIVE trial, published in the New England Journal of Medicine in 2023, pairing early detection with a treatment bundle built around a uterotonic cut the combined risk of severe bleeding, emergency surgery for bleeding, or death from bleeding to 1.6%, versus 4.3% under usual care, a 60% reduction, across 80 hospitals in four African countries.
What is the WHO's standard recommendation to prevent postpartum hemorrhage?
The World Health Organization recommends that every woman receive a uterotonic, usually 10 IU of oxytocin, immediately after birth, whether or not bleeding has started. Postpartum hemorrhage remains the leading cause of maternal death worldwide, affecting an estimated 14 million women and killing around 70,000 each year.
The next one is being invented now.
We send you the day's real progress every morning: the breakthroughs, the quiet wins, the proof it's still happening. Free, forever.
Free forever, no spam. One click to unsubscribe, and we never sell your email.